Nanobody-derived bispecific CAR-T therapy enhances anti-tumor efficacy of T-cell lymphoma treatment

Baijin Xia,Keming Lin,Xuemei Wang,FeiLi Chen,Mo Zhou,Yuzhuang Li,Yingtong Lin,Yidan Qiao,Rong Li,Wanying Zhang,Xin He,Fan Zou,Linghua Li,Lijuan Lu,Cancan Chen,WenYu Li,Hui Zhang,Bingfeng Liu

DOI: https://doi.org/10.1016/j.omto.2023.07.007

2023-07-29

Abstract:T-cell lymphoma (TCL) is a highly heterogeneous group of diseases with a poor prognosis and low 5-year overall survival rate. The current therapeutic regimes have relatively low efficacy rates. Clinical studies of single-target chimeric antigen receptor T (CAR-T) therapy in T lymphocytes require large and multiple infusions, increasing the risks and costs of treatment; therefore, optimizing targeted therapy is a way to improve overall prognosis. Despite significant advances in bispecific CAR-T cell therapy to avoid antigen escape in the treatment of B-cell lymphoma, applying this strategy to TCL requires further investigation. Here, we constructed an alpaca nanobody (Nb) phage library and generated high affinity and specificity Nbs targeting CD30 and CD5, respectively. Based on multiple rounds of screening, bispecific NbCD30-CD5-CAR-T cells were constructed and their superior anti-tumor ability against TCL was validated in vitro and in vivo . Our findings demonstrated that Nb-derived bispecific CAR-T cells significantly improved anti-tumor efficacy in T-lymphoma treatment compared to single-target CAR-T cells and bispecific scFv-derived CAR-T cells. Since Nbs are smaller and less immunogenic, the synergistic effect of Nb-based bispecific CAR-T cells may improve their safety and effectivity in future clinical applications.

oncology,medicine, research & experimental